News | May 28, 2025
Sanjivani Paranteral posts Q4 FY25 at Rs. 2.19 Cr
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
Akums invested Rs. 272 crore in capital expenditure during FY25
Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Subscribe To Our Newsletter & Stay Updated
